Kazuki Nozawa, MD· @kazuki_nozawa · X·· 23 hours agoScore70
Body
KEYNOTE-B49
#ESMO26
Pembrolizumab + chemotherapy improved PFS in PD-L1+ HR+/HER2− advanced breast cancer (HR 0.74), with greater benefit in CPS ≥10 (HR 0.59). No significant OS or overall ORR benefit. Immune-mediated AEs were more frequent.
58 views · 2 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Kazuki Nozawa, MD · x.com